Key Takeaways
- Q1 earnings per share reached $7.79, surpassing analyst expectations of $7.60
- Total revenue climbed 5% annually to $68.5 billion, exceeding the $66.3 billion forecast
- 2026 full-year EPS outlook increased to a minimum of $30.35, representing a $0.10 boost
- Shares declined approximately 3% post-earnings amid concerns over pharmacy benefit operations
- David Cordani steps down as CEO on July 1; Brian Evanko appointed successor
Cigna delivered impressive first-quarter results that failed to win over Wall Street. The healthcare giant exceeded expectations on both the top and bottom lines while raising its annual forecast, yet investors sent shares lower.
CIGNA $CI Q1’26 EARNINGS HIGHLIGHTS
🔹 Adj. Revenue: $68.52B (Est. $66.24B) 🟢; +5% y/y
🔹 Adj. Operating EPS: $7.79 (Est. $7.61) 🟢
🔹 Healthcare Adj. Revenue: $11.48B (Est. $11.37B) 🟢
🔹 Healthcare Medical Care Ratio: 79.8% (Est. 81.0%) 🟢
🔹 FY Adj. Operating EPS Guide: At…— Wall St Engine (@wallstengine) April 30, 2026
First-quarter adjusted earnings per share registered at $7.79, representing growth from $6.74 in the comparable period last year and beating the Street consensus of $7.60. Total revenues reached $68.5 billion, marking a 5% year-over-year expansion and topping the anticipated $66.3 billion.
Management elevated its 2026 full-year earnings guidance to no less than $30.35 per share, marking a $0.10 upward revision from earlier projections. This updated midpoint marginally exceeds the analyst consensus estimate of $30.33.
However, shares declined approximately 3% to the $283 range during morning trading despite these positive metrics.
Operational adjusted income grew 12% to reach $2.1 billion versus $1.8 billion in the first quarter of 2025. This expansion was primarily attributed to performance within Cigna Healthcare and Evernorth Health Services divisions.
The Cigna Healthcare segment saw pre-tax adjusted operational income surge 18% to $1.5 billion. The division’s medical care ratio enhanced to 79.8%, an improvement from 82.2% recorded in the prior-year period.
Evernorth’s adjusted revenues totaled $58.4 billion, representing 9% annual growth. The Specialty and Care Services segment income increased 20% to reach $1.1 billion.
PBM Segment Raises Red Flags
The pharmacy benefit management division emerged as the quarter’s trouble spot. TD Cowen analyst Charles Rhyee characterized it as the “only blemish” in an otherwise strong performance, though he emphasized this wasn’t unexpected considering comparable headwinds at UnitedHealth and Elevance Health. His firm maintained a Buy recommendation with a $338 target price.
Leerink Partners analyst Whit Mayo sustained a Market Perform rating, observing that outcomes “look fine” while noting that “not much jumps off the page as particularly surprising.”
Since autumn of last year, Cigna has been restructuring its pharmacy benefit management operations, pivoting toward a “rebate-free” framework amid mounting regulatory scrutiny and widespread criticism regarding pharmaceutical pricing strategies.
Executive Succession Creates Additional Uncertainty
This past February, Cigna’s Express Scripts division became the initial major PBM among the big three to reach a settlement agreement with the Federal Trade Commission concerning insulin pricing disputes. The company denied any wrongdoing, and the settlement terms corresponded with the previously disclosed rebate-free approach.
A significant executive transition looms for the company. CEO David Cordani departs July 1, with Chief Operating Officer Brian Evanko assuming the top position.
The convergence of an ongoing business model transformation, executive leadership succession, and measured analyst responses provides context for why even a quarter featuring both an earnings beat and raised guidance failed to energize the stock.
The quarter’s standout achievements included the enhanced medical care ratio and robust organic expansion within specialty service lines.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
